- Home
- CYN vs BGLC Comparison
CYN vs BGLC Comparison
Compare CYN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- BGLC
- Stock Information
- Founded
- CYN 2013
- BGLC 2017
- Country
- CYN United States
- BGLC Malaysia
- Employees
- CYN N/A
- BGLC N/A
- Industry
- CYN EDP Services
- BGLC Medical Specialities
- Sector
- CYN Technology
- BGLC Health Care
- Exchange
- CYN Nasdaq
- BGLC Nasdaq
- Market Cap
- CYN 9.3M
- BGLC 7.6M
- IPO Year
- CYN 2021
- BGLC N/A
- Fundamental
- Price
- CYN $6.10
- BGLC $0.29
- Analyst Decision
- CYN
- BGLC
- Analyst Count
- CYN 0
- BGLC 0
- Target Price
- CYN N/A
- BGLC N/A
- AVG Volume (30 Days)
- CYN 1.8M
- BGLC 85.6K
- Earning Date
- CYN 11-06-2024
- BGLC 11-15-2024
- Dividend Yield
- CYN N/A
- BGLC N/A
- EPS Growth
- CYN N/A
- BGLC N/A
- EPS
- CYN N/A
- BGLC N/A
- Revenue
- CYN $102,118.00
- BGLC $9,259,858.00
- Revenue This Year
- CYN $18.11
- BGLC N/A
- Revenue Next Year
- CYN $418.19
- BGLC N/A
- P/E Ratio
- CYN N/A
- BGLC N/A
- Revenue Growth
- CYN N/A
- BGLC N/A
- 52 Week Low
- CYN $2.85
- BGLC $0.28
- 52 Week High
- CYN $59.50
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- CYN 61.20
- BGLC 28.15
- Support Level
- CYN $5.64
- BGLC $0.28
- Resistance Level
- CYN $6.75
- BGLC $0.31
- Average True Range (ATR)
- CYN 0.91
- BGLC 0.02
- MACD
- CYN 0.11
- BGLC -0.00
- Stochastic Oscillator
- CYN 48.86
- BGLC 10.41
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.